Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13179767 | 1.00 | HRH4 (0.34) | HRH4HRH3KDM4ELMNARAB9A | |
| SCHEMBL24662658 | 1.00 | HRH4 (0.34) | HRH4HRH3KDM4ELMNARAB9A | |
| SCHEMBL24880399 | 0.85 | GLB1 (0.33) | — | |
| SCHEMBL12371776 | 0.85 | GLB1 (0.33) | — | |
| SCHEMBL24880397 | 0.85 | GLB1 (0.33) | — | |
| SCHEMBL17060525 | 0.85 | GLB1 (0.33) | — | |
| SCHEMBL12124997 | 0.83 | HRH3 (0.45) | HRH4HRH3KDM4ELMNARAB9A | |
| SCHEMBL16841255 | 0.83 | HRH3 (0.45) | HRH4HRH3KDM4ELMNARAB9A | |
| SCHEMBL3538083 | 0.83 | HRH3 (0.45) | HRH4HRH3KDM4ELMNARAB9A | |
| SCHEMBL10293235 | 0.83 | HRH3 (0.45) | HRH4HRH3KDM4ELMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113122050-B | Quantum dot ink and preparation method of quantum dot film | TCL科技集团股份有限公司 | 2022-11-04 | — | — | CN | claimed |
| CN-113122050-B | Quantum dot ink and preparation method of quantum dot film | TCL科技集团股份有限公司 | 2022-11-04 | — | — | CN | disclosed |
| WO-2022221704-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER | HOTSPOT THERAPEUTICS, INC. (US) | 2022-10-20 | — | — | WO | disclosed |
| US-20070254920-A1 | Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use | AERIE PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254920-A1 | Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use | HCAR1, HCAR2, PAICS | HRH4 120/4885HRH3 54/4885KDM4E 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.